Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial

Sabina A. Murphy; Terje R. Pedersen; Zbigniew A. Gaciong; Richard Ceska; Maiat Ezhov; Derek L. Connolly; J. Wouter Jukema; Kalman Toth; Matti J. Tikkanen; Kyungah Im; Stephen D. Wiviott; Christopher E. Kurtz; Narimon Honarpour; Robert R. Giugliano; Anthony C. Keech; Peter S. Sever; Marc S. Sabatine

doi:10.1001/jamacardio.2019.0886

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial

Sabina A. Murphy, Terje R. Pedersen, Zbigniew A. Gaciong, Richard Ceska, Maiat Ezhov, Derek L. Connolly, J. Wouter Jukema, Kalman Toth, Matti J. Tikkanen, Kyungah Im, Stephen D. Wiviott, Christopher E. Kurtz, Narimon Honarpour, Robert R. Giugliano, Anthony C. Keech, Peter S. Sever, Marc S. Sabatine

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	JAMA cardiology
Volume	4
Issue number	7
Pages (from-to)	613-619
Number of pages	7
ISSN	2380-6583
DOIs	https://doi.org/10.1001/jamacardio.2019.0886
Publication status	Published - Jul 2019
MoE publication type	A1 Journal article-refereed

Fields of Science

ACUTE CORONARY SYNDROMES
MYOCARDIAL-INFARCTION
STATIN THERAPY
ATORVASTATIN
METAANALYSIS
PARTICIPANTS
SIMVASTATIN
CHOLESTEROL
REDUCTION
EFFICACY
3121 General medicine, internal medicine and other clinical medicine

Access to Document

10.1001/jamacardio.2019.0886

Cite this

Murphy, S. A., Pedersen, T. R., Gaciong, Z. A., Ceska, R., Ezhov, M., Connolly, D. L., Jukema, J. W., Toth, K., Tikkanen, M. J., Im, K., Wiviott, S. D., Kurtz, C. E., Honarpour, N., Giugliano, R. R., Keech, A. C., Sever, P. S., & Sabatine, M. S. (2019). Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA cardiology, 4(7), 613-619. https://doi.org/10.1001/jamacardio.2019.0886

@article{e6dd8821fbf34221b4bf8dc41aa7af4f,

title = "Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial",

keywords = "ACUTE CORONARY SYNDROMES, MYOCARDIAL-INFARCTION, STATIN THERAPY, ATORVASTATIN, METAANALYSIS, PARTICIPANTS, SIMVASTATIN, CHOLESTEROL, REDUCTION, EFFICACY, 3121 General medicine, internal medicine and other clinical medicine",

author = "Murphy, {Sabina A.} and Pedersen, {Terje R.} and Gaciong, {Zbigniew A.} and Richard Ceska and Maiat Ezhov and Connolly, {Derek L.} and Jukema, {J. Wouter} and Kalman Toth and Tikkanen, {Matti J.} and Kyungah Im and Wiviott, {Stephen D.} and Kurtz, {Christopher E.} and Narimon Honarpour and Giugliano, {Robert R.} and Keech, {Anthony C.} and Sever, {Peter S.} and Sabatine, {Marc S.}",

year = "2019",

month = jul,

doi = "10.1001/jamacardio.2019.0886",

language = "English",

volume = "4",

pages = "613--619",

journal = "JAMA cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "7",

}

Murphy, SA, Pedersen, TR, Gaciong, ZA, Ceska, R, Ezhov, M, Connolly, DL, Jukema, JW, Toth, K, Tikkanen, MJ, Im, K, Wiviott, SD, Kurtz, CE, Honarpour, N, Giugliano, RR, Keech, AC, Sever, PS & Sabatine, MS 2019, 'Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial', JAMA cardiology, vol. 4, no. 7, pp. 613-619. https://doi.org/10.1001/jamacardio.2019.0886

Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease : A Prespecified Analysis From the FOURIER Trial. / Murphy, Sabina A.; Pedersen, Terje R.; Gaciong, Zbigniew A. et al.

In: JAMA cardiology, Vol. 4, No. 7, 07.2019, p. 613-619.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease

T2 - A Prespecified Analysis From the FOURIER Trial

AU - Murphy, Sabina A.

AU - Pedersen, Terje R.

AU - Gaciong, Zbigniew A.

AU - Ceska, Richard

AU - Ezhov, Maiat

AU - Connolly, Derek L.

AU - Jukema, J. Wouter

AU - Toth, Kalman

AU - Tikkanen, Matti J.

AU - Im, Kyungah

AU - Wiviott, Stephen D.

AU - Kurtz, Christopher E.

AU - Honarpour, Narimon

AU - Giugliano, Robert R.

AU - Keech, Anthony C.

AU - Sever, Peter S.

AU - Sabatine, Marc S.

PY - 2019/7

Y1 - 2019/7

KW - ACUTE CORONARY SYNDROMES

KW - MYOCARDIAL-INFARCTION

KW - STATIN THERAPY

KW - ATORVASTATIN

KW - METAANALYSIS

KW - PARTICIPANTS

KW - SIMVASTATIN

KW - CHOLESTEROL

KW - REDUCTION

KW - EFFICACY

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1001/jamacardio.2019.0886

DO - 10.1001/jamacardio.2019.0886

M3 - Article

VL - 4

SP - 613

EP - 619

JO - JAMA cardiology

JF - JAMA cardiology

SN - 2380-6583

IS - 7

ER -